ACC017 vs Dolutegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

ACC017

Developed by Jiangsu Aidea Pharmaceutical Group

Phase 3 in HIVsmall molecule
Partial signal

NCT06719310 · Phase 1/2 · completed

The first stage of this study randomly assigned patients to ACC017 or placebo under double-blind conditions, a strong design, and its primary endpoints include the proportion of patients reaching an undetectable HIV-1 viral load, a disease-defining measure for HIV therapy. However, results have not yet been posted, so whether the drug met that goal is not yet known.

Next expected readout: June 2027 · NCT07711210 (registry estimate)

Reported efficacy

Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE (Day 1- Day 11); HIV-1 RNA viral load change from baseline (Day 11); Proportion of patients with HIV-1 RNA viral load <50 copies/mL (Day 29); Pharmacokinetics parameter: Cτ,ss (Day 10, Day 29); Pharmacokinetics parameter: Cmin,ss (Day 10); Pharmacokinetics parameter: Cmax,ss (Day 10); Pharmacokinetics parameter: AUC0-τ,ss (Day 1- Day 10); Pharmacokinetics parameter: Tmax,ss (Day 1-Day 10); Pharmacokinetics parameter: MRT0-τ,ss (Day 1-Day 10): The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. (not_applicable)

Result source: NCT06719310

Dolutegravir · Tivicay / Triumeq / Dovato / Juluca (component)

Marketed by GlaxoSmithKline and partners

Approved in HIVsmall molecule
Reliable signal

NCT01263015 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled phase 3 trial in 833 participants comparing dolutegravir plus abacavir/lamivudine to Atripla. The primary endpoint of virologic suppression (<50 copies/mL) at week 48 was a hard clinical measure, and the comparison was statistically significant in favor of dolutegravir (88% vs 81%, p=0.003), with the confidence interval excluding zero. The trial was adequately powered and the primary outcome was met, supporting a strong evidence grade.

Next expected readout: November 2026 · NCT04892654 (registry estimate)

Reported efficacy

Proportion of Subjects Responding Based on Plasma HIV-1 RNA <50 c/mL at Week 48: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003). (met)

Result source: NCT01263015

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointACC017Dolutegravir
HIV-1 RNA below 50 copies/mL (week 48)—Trial running · NCT0771122388% vs 85%vs RTG50 mg Once a Day · wk 48 · n 411NCT01227824
12 other results
  • 90% vs 83% 50 mg once daily · wk 48 · n 242 · Phase 3 · primary NCT01449929
  • 88% vs 81% 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · primary NCT01263015
  • 90% vs 93% wk 48 · n 356 · Phase 3 · primary NCT02831673
  • 93% vs 94% wk 48 · n 360 · Phase 3 · primary NCT02831764
  • 71% vs 63% 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 77% vs 70% 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 79% vs 83% wk 144 · n 356 · Phase 3 · secondary NCT02831673
  • 84% vs 84% wk 144 · n 360 · Phase 3 · secondary NCT02831764
  • 84% vs 89% wk 96 · n 356 · Phase 3 · secondary NCT02831673
  • 88% vs 90% wk 96 · n 360 · Phase 3 · secondary NCT02831764
  • 92% vs 93% wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 94% vs 94% wk 24 · n 360 · Phase 3 · secondary NCT02831764
HIV-1 RNA 50 copies/mL or more (week 48)—Trial running · NCT07711223—Not posted · NCT01837277
CD4 count, change (week 48)—Trial running · NCT07711223163 vs 174−11 vs placebo50 mg BID · wk 72 · n 14NCT01568892
44 other results
  • 170 vs 146 50 mg BID · wk 60 · n 14 · Phase 3 · secondary NCT01568892
  • 115 vs 156 50 mg BID · wk 48 · n 14 · Phase 3 · secondary NCT01568892
  • 90.5 vs 125.5 50 mg BID · wk 40 · n 14 · Phase 3 · secondary NCT01568892
  • 48 vs 135.5 50 mg BID · wk 32 · n 14 · Phase 3 · secondary NCT01568892
  • 39 vs 117 50 mg BID · wk 24 · n 14 · Phase 3 · secondary NCT01568892
  • 292.2 vs 286.2 50 mg Once a Day · wk 96 · n 411 · Phase 3 · secondary NCT01227824
  • 281.3 vs 292.9 50 mg Once a Day · wk 84 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 278.6 50 mg Once a Day · wk 72 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 264.2 50 mg Once a Day · wk 60 · n 411 · Phase 3 · secondary NCT01227824
  • 238.9 vs 257.5 50 mg Once a Day · wk 48 · n 411 · Phase 3 · secondary NCT01227824
  • 248.8 vs 230.7 wk 48 · n 248 · Phase 3 · secondary NCT01910402
  • 224.1 vs 239.8 50 mg Once a Day · wk 40 · n 411 · Phase 3 · secondary NCT01227824
  • 230.7 vs 191.4 wk 36 · n 248 · Phase 3 · secondary NCT01910402
  • 223.4 vs 241.3 50 mg Once a Day · wk 32 · n 411 · Phase 3 · secondary NCT01227824
  • 199.3 vs 204.2 50 mg Once a Day · wk 24 · n 411 · Phase 3 · secondary NCT01227824
  • 200.6 vs 163 wk 24 · n 248 · Phase 3 · secondary NCT01910402
  • 378.5 vs 331.6 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 379.5 vs 333.3 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 377.9 vs 327.2 50 mg plus 600/300 mg once daily · wk 132 · n 414 · Phase 3 · secondary NCT01263015
  • 347 vs 311 50 mg plus 600/300 mg once daily · wk 120 · n 414 · Phase 3 · secondary NCT01263015
  • 349.3 vs 298.9 50 mg plus 600/300 mg once daily · wk 108 · n 414 · Phase 3 · secondary NCT01263015
  • 322.6 vs 286 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 315.2 vs 272.1 50 mg plus 600/300 mg once daily · wk 84 · n 414 · Phase 3 · secondary NCT01263015
  • 306.1 vs 269.6 50 mg plus 600/300 mg once daily · wk 72 · n 414 · Phase 3 · secondary NCT01263015
  • 271.3 vs 235.3 50 mg plus 600/300 mg once daily · wk 60 · n 414 · Phase 3 · secondary NCT01263015
  • 267.5 vs 209.5 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · secondary NCT01263015
  • 265.5 vs 216.2 50 mg plus 600/300 mg once daily · wk 40 · n 414 · Phase 3 · secondary NCT01263015
  • 250.5 vs 208.1 50 mg plus 600/300 mg once daily · wk 32 · n 414 · Phase 3 · secondary NCT01263015
  • 216.9 vs 177.8 50 mg plus 600/300 mg once daily · wk 24 · n 414 · Phase 3 · secondary NCT01263015
  • 301.8 vs 303.2 wk 144 · n 270 · Phase 3 · secondary NCT02831673
  • 301.7 vs 296.6 wk 144 · n 296 · Phase 3 · secondary NCT02831764
  • 264.7 vs 253.8 wk 96 · n 301 · Phase 3 · secondary NCT02831673
  • 272 vs 264.6 wk 96 · n 318 · Phase 3 · secondary NCT02831764
  • 265 vs 230 wk 96 · n 350 · Phase 2/3 · secondary NCT02259127
  • 311 vs 230 wk 96 · n 154 · Phase 2/3 · secondary NCT02259127
  • 228 vs 230 wk 96 · n 196 · Phase 2/3 · secondary NCT02259127
  • 222.2 vs 217.7 wk 48 · n 356 · Phase 3 · secondary NCT02831673
  • 225.7 vs 217.2 wk 48 · n 360 · Phase 3 · secondary NCT02831764
  • 192.2 vs 175.1 wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 188.8 vs 163.2 wk 24 · n 360 · Phase 3 · secondary NCT02831764
  • 72 vs 230 wk 96 · n 42 · Phase 2/3 · secondary NCT02259127
  • 39 vs 28 wk 48 · n 40 · Phase 3 · secondary NCT02263326
  • 88 vs 75 wk 24 · n 65 · Phase 2 · secondary NCT03991013
  • 111 vs 101 wk 24 · n 52 · Phase 2 · secondary NCT03851588

HIV-1 RNA below 50 copies/mL (week 48)

ACC017
—Trial running · NCT07711223
Dolutegravir
88% vs 85%vs RTG50 mg Once a Day · wk 48 · n 411NCT01227824
12 other results
  • 90% vs 83% 50 mg once daily · wk 48 · n 242 · Phase 3 · primary NCT01449929
  • 88% vs 81% 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · primary NCT01263015
  • 90% vs 93% wk 48 · n 356 · Phase 3 · primary NCT02831673
  • 93% vs 94% wk 48 · n 360 · Phase 3 · primary NCT02831764
  • 71% vs 63% 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 77% vs 70% 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 79% vs 83% wk 144 · n 356 · Phase 3 · secondary NCT02831673
  • 84% vs 84% wk 144 · n 360 · Phase 3 · secondary NCT02831764
  • 84% vs 89% wk 96 · n 356 · Phase 3 · secondary NCT02831673
  • 88% vs 90% wk 96 · n 360 · Phase 3 · secondary NCT02831764
  • 92% vs 93% wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 94% vs 94% wk 24 · n 360 · Phase 3 · secondary NCT02831764

HIV-1 RNA 50 copies/mL or more (week 48)

ACC017
—Trial running · NCT07711223
Dolutegravir
—Not posted · NCT01837277

CD4 count, change (week 48)

ACC017
—Trial running · NCT07711223
Dolutegravir
163 vs 174−11 vs placebo50 mg BID · wk 72 · n 14NCT01568892
44 other results
  • 170 vs 146 50 mg BID · wk 60 · n 14 · Phase 3 · secondary NCT01568892
  • 115 vs 156 50 mg BID · wk 48 · n 14 · Phase 3 · secondary NCT01568892
  • 90.5 vs 125.5 50 mg BID · wk 40 · n 14 · Phase 3 · secondary NCT01568892
  • 48 vs 135.5 50 mg BID · wk 32 · n 14 · Phase 3 · secondary NCT01568892
  • 39 vs 117 50 mg BID · wk 24 · n 14 · Phase 3 · secondary NCT01568892
  • 292.2 vs 286.2 50 mg Once a Day · wk 96 · n 411 · Phase 3 · secondary NCT01227824
  • 281.3 vs 292.9 50 mg Once a Day · wk 84 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 278.6 50 mg Once a Day · wk 72 · n 411 · Phase 3 · secondary NCT01227824
  • 247.8 vs 264.2 50 mg Once a Day · wk 60 · n 411 · Phase 3 · secondary NCT01227824
  • 238.9 vs 257.5 50 mg Once a Day · wk 48 · n 411 · Phase 3 · secondary NCT01227824
  • 248.8 vs 230.7 wk 48 · n 248 · Phase 3 · secondary NCT01910402
  • 224.1 vs 239.8 50 mg Once a Day · wk 40 · n 411 · Phase 3 · secondary NCT01227824
  • 230.7 vs 191.4 wk 36 · n 248 · Phase 3 · secondary NCT01910402
  • 223.4 vs 241.3 50 mg Once a Day · wk 32 · n 411 · Phase 3 · secondary NCT01227824
  • 199.3 vs 204.2 50 mg Once a Day · wk 24 · n 411 · Phase 3 · secondary NCT01227824
  • 200.6 vs 163 wk 24 · n 248 · Phase 3 · secondary NCT01910402
  • 378.5 vs 331.6 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 379.5 vs 333.3 50 mg plus 600/300 mg once daily · wk 144 · n 414 · Phase 3 · secondary NCT01263015
  • 377.9 vs 327.2 50 mg plus 600/300 mg once daily · wk 132 · n 414 · Phase 3 · secondary NCT01263015
  • 347 vs 311 50 mg plus 600/300 mg once daily · wk 120 · n 414 · Phase 3 · secondary NCT01263015
  • 349.3 vs 298.9 50 mg plus 600/300 mg once daily · wk 108 · n 414 · Phase 3 · secondary NCT01263015
  • 322.6 vs 286 50 mg plus 600/300 mg once daily · wk 96 · n 414 · Phase 3 · secondary NCT01263015
  • 315.2 vs 272.1 50 mg plus 600/300 mg once daily · wk 84 · n 414 · Phase 3 · secondary NCT01263015
  • 306.1 vs 269.6 50 mg plus 600/300 mg once daily · wk 72 · n 414 · Phase 3 · secondary NCT01263015
  • 271.3 vs 235.3 50 mg plus 600/300 mg once daily · wk 60 · n 414 · Phase 3 · secondary NCT01263015
  • 267.5 vs 209.5 50 mg plus 600/300 mg once daily · wk 48 · n 414 · Phase 3 · secondary NCT01263015
  • 265.5 vs 216.2 50 mg plus 600/300 mg once daily · wk 40 · n 414 · Phase 3 · secondary NCT01263015
  • 250.5 vs 208.1 50 mg plus 600/300 mg once daily · wk 32 · n 414 · Phase 3 · secondary NCT01263015
  • 216.9 vs 177.8 50 mg plus 600/300 mg once daily · wk 24 · n 414 · Phase 3 · secondary NCT01263015
  • 301.8 vs 303.2 wk 144 · n 270 · Phase 3 · secondary NCT02831673
  • 301.7 vs 296.6 wk 144 · n 296 · Phase 3 · secondary NCT02831764
  • 264.7 vs 253.8 wk 96 · n 301 · Phase 3 · secondary NCT02831673
  • 272 vs 264.6 wk 96 · n 318 · Phase 3 · secondary NCT02831764
  • 265 vs 230 wk 96 · n 350 · Phase 2/3 · secondary NCT02259127
  • 311 vs 230 wk 96 · n 154 · Phase 2/3 · secondary NCT02259127
  • 228 vs 230 wk 96 · n 196 · Phase 2/3 · secondary NCT02259127
  • 222.2 vs 217.7 wk 48 · n 356 · Phase 3 · secondary NCT02831673
  • 225.7 vs 217.2 wk 48 · n 360 · Phase 3 · secondary NCT02831764
  • 192.2 vs 175.1 wk 24 · n 356 · Phase 3 · secondary NCT02831673
  • 188.8 vs 163.2 wk 24 · n 360 · Phase 3 · secondary NCT02831764
  • 72 vs 230 wk 96 · n 42 · Phase 2/3 · secondary NCT02259127
  • 39 vs 28 wk 48 · n 40 · Phase 3 · secondary NCT02263326
  • 88 vs 75 wk 24 · n 65 · Phase 2 · secondary NCT03991013
  • 111 vs 101 wk 24 · n 52 · Phase 2 · secondary NCT03851588
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

ACC017
The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. NCT06719310 · Phase 1/2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ACC017: 0 of 4 rows · Dolutegravir: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDolutegravir
Dropout rate
17.4%50 mg plus 600/300 mg once dailya
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
26%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
13.6%50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
31.1%50 mg BID
NCT01328041 · Phase 3
8.5%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
10.7%
NCT04585737 · Phase 4 · registry result, not featured evidence
25.6%Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
13.1%Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
—DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
17.6%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
—DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
16.2%DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
11.4%DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
7.8%Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
4.7%Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
15.4%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
0%50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
0%Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
0%Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
23.9%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
0%50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
6.7%50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
1.5%
NCT03991013 · Phase 2 · registry result, not featured evidence
3.8%
NCT03851588 · Phase 2 · registry result, not featured evidence
—Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
3.1%50 mg plus 600/300 mg once dailya
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
2.9%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
2.1%50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
—50 mg once daily
NCT01449929 · Phase 3
3.8%50 mg BID
NCT01328041 · Phase 3
—
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
—
NCT04585737 · Phase 4 · registry result, not featured evidence
—Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
—Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
—DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
4%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
—DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
2.8%DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
2.8%DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
—Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
—
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
7.7%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
—50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
—Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
—
NCT01837277 · Phase 2/3 · registry result, not featured evidence
—50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
—50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
—
NCT03991013 · Phase 2 · registry result, not featured evidence
—
NCT03851588 · Phase 2 · registry result, not featured evidence
—Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
—Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
—Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
—50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
Serious AEs
15.7%50 mg plus 600/300 mg once dailya
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 41 more results
10%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
6.2%50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
—50 mg once daily
NCT01449929 · Phase 3
14.9%50 mg once daily
NCT01449929 · Phase 3
3.3%50 mg once daily
NCT01449929 · Phase 3
25.1%50 mg BID
NCT01328041 · Phase 3
9.9%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
8.1%
NCT04585737 · Phase 4 · registry result, not featured evidence
7.7%Abacavir/Dolutegravir/Lamivudine(A
NCT03016533 · Phase 3 · registry result, not featured evidence · combination
8.2%Dolutegravir (DTG)
NCT03016533 · Phase 3 · registry result, not featured evidence
8.7%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
4.8%DTG 50 mg/ABC 600 mg/3TC 300 mg QD
NCT01910402 · Phase 3 · registry result, not featured evidence
2.1%DTG + 3TC-Continuation Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC-Double Blind Phase
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
10.4%DTG + 3TC-Double-blind Phase + Ope
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
3.6%DTG + 3TC - Continuation Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
—DTG + 3TC - Double-blind Phase
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
10.8%DTG + 3TC - Double-blind Phase + O
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
18%Arm 1: Maternal DTG+FTC/TAF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
18.1%Arm 2: Maternal DTG+FTC/TDF
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
15.4%50 mg OD
NCT01499199 · Phase 3 · registry result, not featured evidence
—50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
35.7%50mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
26.2%Dolutegravir (<14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
10%Dolutegravir (>=14kg Cohort)
NCT02259127 · Phase 2/3 · registry result, not featured evidence
14.9%Dolutegravir - ODYSSEY A (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
6.1%Dolutegravir - ODYSSEY B (>=14kg C
NCT02259127 · Phase 2/3 · registry result, not featured evidence
9.8%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
6.9%50 mg od
NCT02245022 · Phase 2/3 · registry result, not featured evidence
6.7%50 mg BID
NCT05630872 · Phase 2 · registry result, not featured evidence
3.1%
NCT03991013 · Phase 2 · registry result, not featured evidence
0%
NCT03851588 · Phase 2 · registry result, not featured evidence
0%Cohort 1 Stratum 1A
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 1 Stratum 1B
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 1 Stratum 1C
NCT05406583 · Phase 1 · registry result, not featured evidence
7.1%Cohort 2 Stratum 2A
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Cohort 2 Stratum 2B
NCT05406583 · Phase 1 · registry result, not featured evidence
0%Arm 1 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%Arm 2 Dolutegravir
NCT04771754 · Phase 1 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
50 mg plus 600/300 mg once dailya
diarrhoea 22.7%
nasopharyngitis 20.8%
insomnia 17.9%
NCT01263015 · Phase 3 · combination · HIV · phase 3
show 31 more results
50 mg Once a Day
nausea 14.6%
diarrhoea 14.1%
headache 13.6%
NCT01227824 · Phase 3 · HIV · phase 3
50 mg Once a Day
upper respiratory tract infection 8%
syphilis 7.1%
viral upper respiratory tract infection 7.1%
NCT01227824 · Phase 3 · HIV · phase 3
50 mg once daily
diarrhoea 17.8%
headache 16.5%
nausea 16.5%
NCT01449929 · Phase 3
50 mg once daily
viral upper respiratory tract infection 4.1%
gastroenteritis 2.4%
asthenia 1.6%
NCT01449929 · Phase 3
50 mg BID
diarrhoea 22.4%
cough 15.8%
nausea 14.2%
NCT01328041 · Phase 3
insomnia/nightmares 3.9%
alopecia 2%
itching/rash/prurigo 2%
NCT04880395 · Phase 4 · registry result, not featured evidence · combination
nausea 4.7%
fatigue 4%
diarrhea 3.4%
NCT04585737 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 8.7%
headache 8.1%
urinary tract infection 6%
NCT01910402 · Phase 3 · registry result, not featured evidence
nausea 18.5%
headache 11.7%
diarrhoea 9.3%
NCT01910402 · Phase 3 · registry result, not featured evidence
covid-19 6.9%
suspected covid-19 3.4%
headache 3%
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
headache 14.3%
diarrhoea 14%
nasopharyngitis 13.8%
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
covid-19 6%
syphilis 4%
respiratory tract infection viral 3.2%
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 13.6%
upper respiratory tract infection 13.1%
nasopharyngitis 12.2%
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
creatinine renal clearance decreased 83.9%
blood creatinine increased 78.3%
haemoglobin decreased 3.7%
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
creatinine renal clearance decreased 89.8%
blood creatinine increased 83.3%
haemoglobin decreased 9.3%
NCT03048422 · Phase 3 · registry result, not featured evidence · combination
grade 3 bilirubinemia 0%
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
50 mg OD
headache 53.8%
upper respiratory tract infection 38.5%
diarrhoea 30.8%
NCT01499199 · Phase 3 · registry result, not featured evidence
50mg BID
diarrhoea 21.4% (placebo 12.5%)
headache 21.4% (placebo 6.3%)
lymphadenopathy 21.4% (placebo 0%)
NCT01568892 · Phase 3 · registry result, not featured evidence
cns disturbances 0%
NCT01837277 · Phase 2/3 · registry result, not featured evidence
50 mg od
low haemoglobin 6.9%
NCT02245022 · Phase 2/3 · registry result, not featured evidence
50 mg BID
abnormal loss of weight 10%
blood pressure increased 10%
headache 10%
NCT05630872 · Phase 2 · registry result, not featured evidence
acute psychosis 1.5% (placebo 0%)
incident pulmonary tuberculosis 1.5% (placebo 0%)
acute kidney injury 0% (placebo 3.1%)
NCT03991013 · Phase 2 · registry result, not featured evidence
insomnia 5.7% (placebo 0%)
NCT03851588 · Phase 2 · registry result, not featured evidence
haemoglobin decreased 33.3%
alanine aminotransferase increased 16.7%
aspartate aminotransferase increased 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 50%
alanine aminotransferase increased 16.7%
blood bilirubin increased 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 83.3%
neutrophil count decreased 50%
acne infantile 16.7%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 42.9%
blood bilirubin increased 35.7%
dermatitis diaper 21.4%
NCT05406583 · Phase 1 · registry result, not featured evidence
haemoglobin decreased 56.3%
neutrophil count decreased 31.3%
blood bilirubin increased 25%
NCT05406583 · Phase 1 · registry result, not featured evidence
hypokalaemia 71.4% (placebo 71.4%)
hypoglycaemia 42.9% (placebo 71.4%)
vivid dreams 28.6% (placebo 0%)
NCT04771754 · Phase 1 · registry result, not featured evidence
hypokalaemia 62.5% (placebo 71.4%)
cold 25% (placebo 14.3%)
bloating 12.5% (placebo 0%)
NCT04771754 · Phase 1 · registry result, not featured evidence
50mg/25mg
headache 6.3%
vessel puncture site bruise 6.3%
vomiting 6.3%
NCT03984838 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 39 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dolutegravir

HIV-1 RNA Less Than 50 Copies 88% (n=411) vs 85% (n=411) RTG @ 48wk50 mg Once a Day
responder rate · % of participants
NCT01227824 · Phase 3 · HIV · phase 3
show 12 more results
90% (n=242) vs 83% (n=242) DRV + RTV @ 48wk50 mg once daily
NCT01449929 · Phase 3
88% (n=414) vs 81% (n=419) EFV/TDF/FTC @ 48wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
77% (n=414) vs 70% (n=419) EFV/TDF/FTC @ 96wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
71% (n=414) vs 63% (n=419) EFV/TDF/FTC @ 144wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
90% (n=356) vs 93% (n=358) DTG + TDF/FTC @ 48wk
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
92% (n=356) vs 93% (n=358) DTG + TDF/FTC @ 24wk
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
84% (n=356) vs 89% (n=358) DTG + TDF/FTC @ 96wk
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
79% (n=356) vs 83% (n=358) DTG + TDF/FTC @ 144wk
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
93% (n=360) vs 94% (n=359) DTG + TDF/FTC @ 48wk
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
94% (n=360) vs 94% (n=359) DTG + TDF/FTC @ 24wk
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
88% (n=360) vs 90% (n=359) DTG + TDF/FTC @ 96wk
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
84% (n=360) vs 84% (n=359) DTG + TDF/FTC @ 144wk
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
Time to Viral Suppression 0.92 vs 2.79 DRV + RTV months50 mg once daily
time to event · months
NCT01449929 · Phase 3 · converted to months from 28 days as posted
show 3 more results
0.92 vs 2.76 EFV/TDF/FTC months*50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3 · converted to months from 28 days as posted
0.95 vs 0.95 DTG + TDF/FTC months @ 144wk*
NCT02831673 · Phase 3 · registry result, not featured evidence · combination · converted to months from 29 days as posted
0.95 vs 0.95 DTG + TDF/FTC months*
NCT02831764 · Phase 3 · registry result, not featured evidence · combination · converted to months from 29 days as posted
Virologic Failure 2.7% (n=414) vs 1.9% (n=419) EFV/TDF/FTC50 mg plus 600/300 mg once daily
event count · % of participants
ACTG virologic failures
NCT01263015 · Phase 3 · combination · HIV · phase 3 · converted to % from 11 Participants as posted
HIV-1 RNA -1.06 vs 0.1 placebo log @ 1.142857wk50 mg BID
absolute change · log
NCT01568892 · Phase 3 · registry result, not featured evidence
show 52 more results
-1.07 vs -0.03 placebo log @ 1.14wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-1.87 vs -2.12 placebo log @ 4wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-1.89 vs -2.32 placebo log @ 8wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-1.54 vs -2.02 placebo log @ 12wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-1.48 vs -2.24 placebo log @ 16wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-1.38 vs -2.53 placebo log @ 24wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-1.31 vs -2.62 placebo log @ 32wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-1.48 vs -2.7 placebo log @ 40wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-1.34 vs -2.77 placebo log @ 48wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-1.91 vs -2.71 placebo log @ 60wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-2.08 vs -3.31 placebo log @ 72wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
-2.817 vs -2.801 RTG log @ 4wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.897 vs -2.886 RTG log @ 8wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.908 vs -2.918 RTG log @ 12wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.917 vs -2.943 RTG log @ 16wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.896 vs -2.933 RTG log @ 24wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.907 vs -2.947 RTG log @ 32wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.92 vs -2.946 RTG log @ 40wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.915 vs -2.942 RTG log @ 48wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.912 vs -2.937 RTG log @ 60wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.917 vs -2.932 RTG log @ 72wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.932 vs -2.916 RTG log @ 84wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.938 vs -2.901 RTG log @ 96wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
-2.8 vs -2.01 DRV + RTV log @ 4wk50 mg once daily
NCT01449929 · Phase 3
-2.86 vs -2.4 DRV + RTV log @ 8wk50 mg once daily
NCT01449929 · Phase 3
-2.88 vs -2.61 DRV + RTV log @ 12wk50 mg once daily
NCT01449929 · Phase 3
-2.86 vs -2.71 DRV + RTV log @ 16wk50 mg once daily
NCT01449929 · Phase 3
-2.86 vs -2.83 DRV + RTV log @ 24wk50 mg once daily
NCT01449929 · Phase 3
-2.87 vs -2.85 DRV + RTV log @ 36wk50 mg once daily
NCT01449929 · Phase 3
-2.89 vs -2.86 DRV + RTV log @ 48wk50 mg once daily
NCT01449929 · Phase 3
-2.591 vs -1.923 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD log @ 4wk
NCT01910402 · Phase 3 · registry result, not featured evidence
-2.756 vs -2.541 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD log @ 12wk
NCT01910402 · Phase 3 · registry result, not featured evidence
-2.789 vs -2.726 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD log @ 24wk
NCT01910402 · Phase 3 · registry result, not featured evidence
-2.838 vs -2.772 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD log @ 36wk
NCT01910402 · Phase 3 · registry result, not featured evidence
-2.874 vs -2.752 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD log @ 48wk
NCT01910402 · Phase 3 · registry result, not featured evidence
-2.46 vs -1.96 EFV/TDF/FTC log @ 2wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-2.88 vs -2.25 EFV/TDF/FTC log @ 4wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-2.99 vs -2.6 EFV/TDF/FTC log @ 8wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.01 vs -2.85 EFV/TDF/FTC log @ 12wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.03 vs -2.98 EFV/TDF/FTC log @ 16wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.05 vs -3.01 EFV/TDF/FTC log @ 24wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.04 vs -3.05 EFV/TDF/FTC log @ 32wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.05 vs -3.04 EFV/TDF/FTC log @ 40wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.03 vs -3.04 EFV/TDF/FTC log @ 48wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.03 vs -3.05 EFV/TDF/FTC log @ 60wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.03 vs -3.06 EFV/TDF/FTC log @ 72wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.02 vs -3.07 EFV/TDF/FTC log @ 84wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-2.99 vs -3.06 EFV/TDF/FTC log @ 96wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.01 vs -3.08 EFV/TDF/FTC log @ 108wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3 vs -3.07 EFV/TDF/FTC log @ 120wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.03 vs -3.06 EFV/TDF/FTC log @ 132wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
-3.02 vs -3.04 EFV/TDF/FTC log @ 144wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
CD4+ 7 vs 0 placebo cells/uL @ 1.14wk50 mg BID
absolute change · cells/uL
NCT01568892 · Phase 3 · registry result, not featured evidence
show 59 more results
14 vs 68.5 placebo cells/uL @ 4wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
34 vs 87.5 placebo cells/uL @ 8wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
49 vs 79 placebo cells/uL @ 12wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
76.5 vs 70 placebo cells/uL @ 16wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
39 vs 117 placebo cells/uL @ 24wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
48 vs 135.5 placebo cells/uL @ 32wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
90.5 vs 125.5 placebo cells/uL @ 40wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
115 vs 156 placebo cells/uL @ 48wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
170 vs 146 placebo cells/uL @ 60wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
163 vs 174 placebo cells/uL @ 72wk50 mg BID
NCT01568892 · Phase 3 · registry result, not featured evidence
93.3 vs 97.2 RTG cells/uL @ 4wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
121.6 vs 126.6 RTG cells/uL @ 8wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
130.7 vs 145.1 RTG cells/uL @ 12wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
155.1 vs 173 RTG cells/uL @ 16wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
199.3 vs 204.2 RTG cells/uL @ 24wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
223.4 vs 241.3 RTG cells/uL @ 32wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
224.1 vs 239.8 RTG cells/uL @ 40wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
238.9 vs 257.5 RTG cells/uL @ 48wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
247.8 vs 264.2 RTG cells/uL @ 60wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
247.8 vs 278.6 RTG cells/uL @ 72wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
281.3 vs 292.9 RTG cells/uL @ 84wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
292.2 vs 286.2 RTG cells/uL @ 96wk50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3
94.9 vs 73.7 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD cells/uL @ 4wk
NCT01910402 · Phase 3 · registry result, not featured evidence
143.8 vs 124.4 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD cells/uL @ 12wk
NCT01910402 · Phase 3 · registry result, not featured evidence
200.6 vs 163 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD cells/uL @ 24wk
NCT01910402 · Phase 3 · registry result, not featured evidence
230.7 vs 191.4 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD cells/uL @ 36wk
NCT01910402 · Phase 3 · registry result, not featured evidence
248.8 vs 230.7 ATV 300 mg+RTV 100 mg+TDF 300 mg/FTC 200 mg QD cells/uL @ 48wk
NCT01910402 · Phase 3 · registry result, not featured evidence
378.48 vs 331.57 EFV/TDF/FTC cells/uL @ 144wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
117.6 vs 80.9 EFV/TDF/FTC cells/uL @ 4wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
164.6 vs 124.4 EFV/TDF/FTC cells/uL @ 8wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
187.5 vs 153 EFV/TDF/FTC cells/uL @ 12wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
214.7 vs 174.1 EFV/TDF/FTC cells/uL @ 16wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
216.9 vs 177.8 EFV/TDF/FTC cells/uL @ 24wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
250.5 vs 208.1 EFV/TDF/FTC cells/uL @ 32wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
265.5 vs 216.2 EFV/TDF/FTC cells/uL @ 40wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
267.5 vs 209.5 EFV/TDF/FTC cells/uL @ 48wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
271.3 vs 235.3 EFV/TDF/FTC cells/uL @ 60wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
306.1 vs 269.6 EFV/TDF/FTC cells/uL @ 72wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
315.2 vs 272.1 EFV/TDF/FTC cells/uL @ 84wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
322.6 vs 286 EFV/TDF/FTC cells/uL @ 96wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
349.3 vs 298.9 EFV/TDF/FTC cells/uL @ 108wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
347 vs 311 EFV/TDF/FTC cells/uL @ 120wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
377.9 vs 327.2 EFV/TDF/FTC cells/uL @ 132wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
379.5 vs 333.3 EFV/TDF/FTC cells/uL @ 144wk50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
192.2 vs 175.1 DTG + TDF/FTC cells/uL @ 24wk
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
222.2 vs 217.7 DTG + TDF/FTC cells/uL @ 48wk
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
264.7 vs 253.8 DTG + TDF/FTC cells/uL @ 96wk
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
301.8 vs 303.2 DTG + TDF/FTC cells/uL @ 144wk
NCT02831673 · Phase 3 · registry result, not featured evidence · combination
188.8 vs 163.2 DTG + TDF/FTC cells/uL @ 24wk
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
225.7 vs 217.2 DTG + TDF/FTC cells/uL @ 48wk
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
272 vs 264.6 DTG + TDF/FTC cells/uL @ 96wk
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
301.7 vs 296.6 DTG + TDF/FTC cells/uL @ 144wk
NCT02831764 · Phase 3 · registry result, not featured evidence · combination
39 vs 28 current ART regimen cells/uL @ 48wk
NCT02263326 · Phase 3 · registry result, not featured evidence · combination
265 vs 230 Standard of Care cells/uL @ 96wk
NCT02259127 · Phase 2/3 · registry result, not featured evidence
72 vs 230 Standard of Care cells/uL @ 96wk
NCT02259127 · Phase 2/3 · registry result, not featured evidence
311 vs 230 Standard of Care cells/uL @ 96wk
NCT02259127 · Phase 2/3 · registry result, not featured evidence
228 vs 230 Standard of Care cells/uL @ 96wk
NCT02259127 · Phase 2/3 · registry result, not featured evidence
88 vs 75 placebo cells/uL @ 24wk
NCT03991013 · Phase 2 · registry result, not featured evidence
111 vs 101 placebo cells/uL @ 24wk
NCT03851588 · Phase 2 · registry result, not featured evidence
Symptom Bother -3.2 vs -2.19 DRV + RTV score @ 4wk50 mg once daily
absolute change · score
NCT01449929 · Phase 3
show 3 more results
-2.71 vs -1.65 DRV + RTV score @ 24wk50 mg once daily
NCT01449929 · Phase 3
-2.46 vs -0.77 DRV + RTV score @ 48wk50 mg once daily
NCT01449929 · Phase 3
-1.818 vs -1.246 EFV/TDF/FTC score50 mg plus 600/300 mg once daily
NCT01263015 · Phase 3 · combination · HIV · phase 3
HIV-1 RNA Less Than 50 80.8% (n=411) vs 76.4% (n=411) RTG @ 96wk50 mg Once a Day
event count · % of participants
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 332 Participants as posted
HIV-1 RNA Less Than 400 89.8% (n=411) vs 86.6% (n=411) RTG @ 48wk50 mg Once a Day
event count · % of participants
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 369 Participants as posted
show 1 more result
82.2% (n=411) vs 78.1% (n=411) RTG @ 96wk*50 mg Once a Day
NCT01227824 · Phase 3 · HIV · phase 3 · converted to % from 338 Participants as posted
HIV-1 RNA Less Than 400 Copies 92% (n=242) vs 87% (n=242) DRV + RTV @ 48wk50 mg once daily
responder rate · % of participants
NCT01449929 · Phase 3
CD4+ 80.1 vs 75.6 DRV + RTV cells/uL @ 4wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 4, n=237, 236
NCT01449929 · Phase 3
CD4+ 126.9 vs 118.8 DRV + RTV cells/uL @ 8wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 8, n=236, 236
NCT01449929 · Phase 3
CD4+ 135.2 vs 131.8 DRV + RTV cells/uL @ 12wk50 mg once daily
absolute change · cells/uL
CD4+ cell count, Week 12, n=234, 228
NCT01449929 · Phase 3

+ 81 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACC017's landscape · Dolutegravir's landscape